WO2001023393A1 - 3-cephem derivative crystal and method for preparing the same - Google Patents
3-cephem derivative crystal and method for preparing the same Download PDFInfo
- Publication number
- WO2001023393A1 WO2001023393A1 PCT/JP2000/006693 JP0006693W WO0123393A1 WO 2001023393 A1 WO2001023393 A1 WO 2001023393A1 JP 0006693 W JP0006693 W JP 0006693W WO 0123393 A1 WO0123393 A1 WO 0123393A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivative
- group
- cefm
- crystal
- carbon dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Definitions
- the present invention relates to a 3-sefm derivative crystal and a production method thereof.
- the present invention relates to, for example, cefixime, ceftibutene, and cefdinir, which are currently widely used pharmaceutical antibiotics (The latest antibiotics handbook, written by Katsuharu Sakai, 83, 8)
- the present invention relates to a 3-cephem derivative in a crystalline state obtained by a novel crystallization method, and a method for producing the same, which is useful as a pharmaceutical intermediate or a final product such as a pharmaceutical intermediate (p. 5 and 86).
- Background art
- the crystallization method of 3-cefm derivatives has been generally performed using a combination of a good solvent with high substrate solubility and a poor solvent with low substrate solubility.
- Amorphous powders are more susceptible to problems such as filter cloth leakage and clogging during filtration than crystalline powders, resulting in extremely long filtration times and poor purity due to poor cleaning.
- the temperature dependence of the solubility of the substrate in the solvent used is large, so that under moderate conditions near room temperature, the filtrate port generally increases, and a sufficient yield cannot be obtained. .
- the 3-CFM derivative has a strong affinity for organic solvents, so conventional crystallization methods that use large amounts of organic solvents require a large amount of organic solvent to be adsorbed, making it extremely difficult to remove residual solvents by drying. In many cases.
- 3-Cef induction of amorphous powder The body generally had poor thermal stability and was difficult to dry at high temperatures, so drying under high vacuum was necessary. For this reason, there has been a strong demand for the development of a new crystallization method for 3-Cefem derivatives, which could only obtain an amorphous powder by the conventional crystallization method.
- An object of the present invention is to provide a novel crystal production method for obtaining a highly purified crystalline form of a 3-cephem derivative from an amorphous powder or an oily substance, the stability of which is very important. It is in. Disclosure of the invention
- the present invention provides a method for crystallizing an amorphous powder or an oily 3-cefm derivative by using a good solvent and a poor solvent comprising carbon dioxide in a supercritical state or a subcritical state to obtain a crystalline state.
- the present invention relates to a method for producing a 3-Cef derivative crystal, characterized by obtaining a Cef derivative.
- the present invention is characterized in that a supercritical state or a subcritical state carbon dioxide is introduced into a reaction solution in a production process of a 3-cef derivative under pressure, thereby obtaining a crystalline 3-cef derivative.
- the present invention relates to a method for producing a 3-Cef derivative crystal.
- the present invention is characterized by obtaining a crystalline 3-cephem derivative by introducing a reaction solution in a process for producing a 3-cef derivative under pressure into carbon dioxide in a supercritical or subcritical state.
- the present invention relates to a method for producing a cefm derivative crystal.
- the present invention also relates to a 3-cephem derivative crystal, which is an inclusion compound of p-methoxybenzyl ester of 7-phenylacetamido-3-formyl-3-cefm-4-carboxylic acid and dimethylformamide.
- the present inventors have paid attention to the fact that carbon dioxide in a supercritical state or a subcritical state has a very large permeability and diffusivity, and at the same time, has a strong ability to form a cluster with an organic compound (substrate).
- an inclusion compound may be formed depending on the combination of the 3-cef derivative and a good solvent. These cases are also included. More specifically, for example, 7-phenylacetamide-3-formyl-3-cephem-4-carboxylic acid p-methoxybenzyl ester [3-formylseph compound (1)] as a 3-cef derivative, and dimethylformamide (3) as a good solvent When DMF) is used, clathrates are formed by both.
- An inclusion compound is a compound with a structure in which two molecules combine to form crystals under appropriate conditions, and one of the molecules forms a tunnel, layer, or network structure, and the other molecule enters the gap. That is.
- 3-formylcephem compound (1) 7-phenylacetoamide-3-formyl-13-cephemu-4-carboxylic acid p-methoxybenzyl ester represented by the following formula (1) (hereinafter referred to as "3-formylcephem compound (1)" unless otherwise specified) )
- the currently widely used antibiotics Is very useful as a synthetic intermediate such as cefixime (the latest antibiotics handbook, 10th edition, written by Katsuharu Sakai, p. 83).
- 3-formylcephem compound (1) has been prepared, for example, according to the method described in Tet rahedron Lett., 23, 2187 (1992), 7-phenylacetamide 3-chloromethyl.
- C-FM-p-methoxybenzyl ester is produced, and the ester is reacted with potassium iodide.
- the chlorine atom in the ester is replaced with an iodine atom to give 7-phenylacetamide.
- 3-odomethylsefume 4-carboxylic acid p-methoxybenzyl ester which was prepared according to the method described in Synlett, 660 (1990) ⁇ Japanese Patent Application Laid-Open No. 3-2588783. According to oxygen It is produced as an oil or an amorphous powder by oxidation.
- the 3-formylsefm compound (1) has the property that, in the form of a solution, an oily substance or an amorphous powder, the formyl group is easily subjected to air oxidation to cause a decomposition reaction (Test Example 1). Therefore, when an antibiotic such as cefixim is produced from a 3-formylcefm compound (1) on an industrial scale, the target antibiotic is obtained in high yield and high purity by decomposition of the compound (1). I can't do that. Moreover, even if a known crystallization method such as a crystallization method using a poor solvent is applied to these oils or amorphous powders in order to reduce the decomposability, crystals cannot be grown, and the obtained crystals are obtained. These are only amorphous powders (Reference Example 2).
- An object of the present invention is to provide a crystal of a 3-formylsefm compound (1) which is stable and does not undergo decomposition while retaining the high reactivity inherent in the 3-formylsefm compound (1). It is.
- the present invention provides a method for dissolving a 3-cefm derivative of an amorphous powder or an oily substance in a good solvent, and crystallizing the crystal by using a crystal obtained by the method according to claim 1 as a seed crystal.
- the present invention relates to a method for producing a characteristic 3-Cefm derivative crystal. That is, for example, once the supercritical or subcritical carbon dioxide is obtained as a poor solvent by a crystallization method according to the method described in claim 1 above, the crystalline 3-cefm derivative is obtained.
- a 3-cefm derivative crystal can be obtained very easily from an amorphous powder or oily 3-cefm derivative without using any supercritical or subcritical carbon dioxide. Such an easy way It is the first achievement of the present invention that high purity 3-Cefm derivative crystals can be obtained.
- 3-cefm derivative for example, a 3-cefm derivative of the formula (2) can be exemplified.
- R 1 or R 2 may be the same or different, and represents a hydrogen atom, a halogen atom, a group OR 5 (R 5 represents a lower alkyl group which may have a substituent, an aryl group or a benzyl group. ), An amino group which may have a substituent, and a protected amino group.
- R 3 represents a hydrogen atom or a carboxylic acid protecting group
- B represents a lower alkylene group, a lower alkenylene group
- n represents 0 or 1.
- R 4 is a hydrogen atom, a hydroxyl group, an octogen atom, a formyl group, a tertiary amino group which may itself have a cyclic structure, a group OR 5 (R 5 is the same as above), a group SR 6 (R 6 represents a lower alkyl group, a lower alkenyl group, a benzyl group, an aryl group, or a heterocyclic hydrocarbon group which may have a substituent, and a group OS 0 2 R 7 (R 7 is a halogen atom or a substituted Represents a lower alkyl group or an aryl group which may have a group).
- a solution is prepared by adding a good solvent to an amorphous powder or oily 3-cefm derivative, or carbon dioxide in a supercritical state or subcritical state is added to a reaction solution in the production process under pressure.
- a good solvent to an amorphous powder or oily 3-cefm derivative, or carbon dioxide in a supercritical state or subcritical state is added to a reaction solution in the production process under pressure.
- the reaction solution in the production process of the 3-cefm derivative is introduced under pressure into carbon dioxide in a supercritical state or a subcritical state, whereby the carbon dioxide in the crystalline state can be obtained.
- the halogen atom is fluorine, chlorine, bromine, or iodine.
- the lower alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and sec. It is a linear or branched alkyl group having 1 to 4 carbon atoms such as a monobutyl group and a tert-butyl group, and the lower alkylene group is a carbon atom such as a methylene group, an ethylene group, a propylene group, and a tetramethylene group.
- the lower alkenyl group is a linear or branched alkenyl having 2 to 4 carbon atoms such as a vinyl group, a propenyl group, and a butenyl group.
- a lower alkylene group means a linear or branched alkenylene group having 2 to 4 carbon atoms, such as a vinylene group, a probenylene group, a butenylene group or the like.
- the aryl group means, for example, a phenyl group or a naphthyl group
- the heterocyclic hydrocarbon group includes, for example, a phenyl group, a furyl group, a piperidyl group, a pyridyl group, an imidazolyl group, a benzotriazolyl group, a tetrazolyl group.
- X represents a hydrogen atom, an amino group, or an amino group substituted with a COA group ( ⁇ is a heterocyclic hydrocarbon group which may have a substituent).
- ⁇ is a heterocyclic hydrocarbon group which may have a substituent.
- ⁇ can be mentioned a lower alkyl group, hydroxyl group, a Kiichi OR 5.
- Q represents a methylidine group or a nitrogen atom.
- Examples of the substituent of the lower alkyl group represented by R 5 to R 7 include a halogen atom, a carbonyl group, a hydroxyl group, a nitro group, a cyano group, an amino group, a mercapto group, an aryl group, an alkylthio group, and an arylthio group.
- Heterocyclic hydrocarbon in R 6 Examples of the substituent of the basic group include a lower alkyl group, a halogen atom, a carboxyl group, a hydroxyl group, a nitro group, a cyano group, an amino group, a mercapto group, an aryl group, an alkylthio group, and an arylthio group.
- R 1 examples include Protective Group in Organic Synthes is, Theodora W. Greene, 1989, hereinafter simply referred to as “Literature”.
- R i and R j may be the same or different and each represent a hydrogen atom, a lower alkyl group, an aryl group, or a heterocyclic hydrocarbon group, or R i and R j are each other Represents a cyclic group which may be bonded.
- the protecting group of the carboxylic acid represented by R 3 various other groups listed in chapter 5 of the document (first 5 2-1 9 2 pages), Ariru group, a benzyl group, p- methoxy Benzyl group, p-nitrobenzyl group, diphenylmethyl group, trichloromethyl group, tert-butyl group and the like.
- Examples of the tertiary amino group which may have a cyclic structure itself represented by R 4 include, for example, a dimethylamino group, a getylamino group, a methylethylamino group, a dicyclopropylamino group, a morpholino group, a pyridinyl group, and a piperazinyl group , Imidazolyl group, tetrazolyl group and the like.
- Good solvents used in the present invention include lower alkyl alcohols such as methanol, ethanol and propanol, methyl formate, ethyl formate, propyl formate, butyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate and methyl propionate.
- Lower alkyl esters of lower alkyl carboxylic acids such as tyl and ethyl propionate; ketones such as acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, and getyl ketone; Ethers such as ether, ethyl butyl ether, dipropyl ether, diisopropyl ether, dibutyl ether, methyl sorb, dimethoxyethane, etc., and cyclic compounds such as tetrahydrofuran, dioxane, dioxolane Ichite Le acids, Asetonitoriru, propionic nitrile, butyronitrile, Isopuchironitori Le, nitriles such as Bruno Reronitoriru, benzene, toluene, xylene, black hole Aromatic hydrocarbons such as benzene, anisol
- the good solvent means a solvent that dissolves the 3-cefm derivative of the present invention.
- These organic solvents are used alone or in combination of two or more. These solvents are generally used in an amount of about 0.1 L to 200 L, preferably about 1 to 100 L, per kg of the compound of the formula (1).
- these organic solvents may contain water as necessary.
- the proportion of water that may be contained is 0.1 to 20% by volume, preferably 0.5 to 10% by volume, based on the organic solvent used.
- the critical point of carbon dioxide is a temperature of 3 1 "C and a pressure of 7.3 MPa, and carbon dioxide having a temperature and pressure exceeding this is called supercritical carbon dioxide. Carbon dioxide having a pressure of around 30) and pressure (around 6-7.2MPa) is called subcritical carbon dioxide.
- the pressure of the supercritical or subcritical carbon dioxide used in the present invention is usually about 3 to 40 MPa, preferably about 6 to 3 OMPa.
- the temperature at which the crystallization is carried out depends on the pressure, but it is usually about 5 to about 70, preferably about 20 to about 50.
- the ratio of supercritical or subcritical carbon dioxide to organic solvent varies depending on the organic solvent used, the substrate, and the temperature and pressure during crystallization of carbon dioxide, but is usually 10:90 to 99: 1. Degree, desirably 30:70 to 90:10.
- the supercritical or subcritical carbon dioxide used here can be easily recovered by lowering the pressure, the carbon dioxide recovered during crystallization, filtration, and washing is used. It is also possible to use the recovered carbon dioxide which has made the carbon oxide supercritical or subcritical again.
- a method for producing a 3-sefm derivative crystal which comprises crystallizing using a crystal obtained by a crystallization method using carbon dioxide in a supercritical state or a subcritical state as a poor solvent according to the present invention as a seed crystal
- Solvents for dissolving the amorphous powder or oily 3-Chem derivative may be the same organic solvents as those used to dissolve the amorphous powder or oily 3-Chem derivative when obtaining the above-mentioned 3-Chem derivative crystals. Solvents can be used. These organic solvents are used alone or in combination of two or more. The amount of the organic solvent to be used is preferably such that the amount of the 3-cefm derivative dissolved is supersaturated or nearly supersaturated.
- a solvent having a poor solubility of the 3-cefm derivative as compared with the above-mentioned organic solvent which is a good solvent can be used in combination, if necessary.
- a comparative poor solvent include water, getyl ether, diisopropyl ether, pentane, hexane, heptane, octane and the like.
- the amount of the poor solvent to be used is 0.1 to 20% by volume, preferably 0.5 to 10% by volume, based on the organic solvent.
- the amount of the seed crystal used is preferably about 0.1 to 10% by weight based on the amorphous powder or oil used.
- the crystallization method using the seed crystal of the present invention is preferably performed within the range of 110 to 30. Also in the crystallization method using the seed crystal of the present invention, an inclusion compound crystal may be formed depending on the combination of the applied 3-Chem derivative and the solvent used.
- antibiotics such as cefixime can be obtained in a high yield of 90% or more and 95% or more. It can be manufactured with the above high purity.
- the measurement of the X-ray powder diffraction spectrum was performed under the following measurement conditions using an apparatus called RAD-IIA manufactured by Rigaku Corporation.
- Source Copper radiation with a wavelength of 1.54 18 angstroms through a monochromator.
- the ratio of the crystal of the 3-formylcephem compound (1) and dimethylformamide is determined by the ratio of the use of both, the supercritical or subcritical carbon dioxide. It varies depending on the amount used, temperature and pressure, temperature conditions for crystallization, etc., but usually 1 to 99 mol%, preferably 40 to 90 mol% of the crystals of the 3-formylcephem compound (1). Mol%.
- the crystal of the 3-formylsephem compound (1) of the present invention is an inclusion crystal of the 3-formylsepheme compound (1) and dimethylformamide, for example, from the integration ratio of the i H—NMR spectrum. You can check.
- the crystals of the 3-formylsephem compound (1) according to the present invention are obtained by dissolving the amorphous powder and / or oily substance of the 3-formylsepheme compound (1) in hydrous dimethylformamide, It can be produced by introducing critical carbon dioxide for crystallization.
- the water content of the water-containing dimethylformamide is not particularly limited, but is usually 0.2 to 20% by volume, preferably 1 to 10% by volume.
- One or more organic solvents other than dimethylformamide can be used together with dimethylformamide.
- the organic solvent is not particularly limited as long as it has good compatibility with dimethylformamide and does not adversely affect the crystallization reaction. Examples thereof include amide solvents such as methylformamide and dimethylacetamide. Can be mentioned.
- the proportion of the dimethylformamide used in combination with dimethylformamide is not particularly limited, but dimethylformamide may be contained at 3% by volume or more, preferably at least 10% by volume.
- the thus-obtained crystals of the 3-formylsefm compound (1) can be isolated from the reaction system according to known purification means.
- the cephalosporin crystals precipitated in the reaction system may be collected by filtration and dried at normal pressure or reduced pressure, preferably at a temperature of about 25 to 45.
- the crystal of the 3-formylcephem compound (1) of the present invention can be, for example, an intermediate in the synthesis of the aforementioned antibiotic cefixime.
- the synthesis of cefixime can be performed according to the following reaction formula.
- FIG. 1 shows the 1 H-NMR spectrum of the 3-Cefem derivative crystal of the present invention obtained in Example 1.
- the above-mentioned dimethylformamide solution is dropped into sufficiently cooled isopropyl alcohol, and the mixture is stirred for 1 hour while maintaining the internal temperature at 5 ° C to 10 ° C, whereby a powder of 3-formyl cefm compound (1) precipitates. After aging, the precipitate is filtered. After filtration, wash with 5 ° C isopropyl alcohol 3 O Oml.
- the crystalline 3-formylcephem compound (1) obtained by the present invention is an important synthetic intermediate such as cefixime.
- the crystalline dimethylformamide clathrate of the crystalline 3-formylcephem compound (1) obtained in Example 1 was reacted with methyltriphenylphosphonium iodide and sodium carbonate to give 7-phenylacetamide-3- Vinyl 3-cef-4 p-Methoxybenzyl ester, treated with phosphorus pentachloride / pyridine, and then added with isobutanol to give 7-amino-3-vinyl-3-cefem-4-carbone
- the acid is p-methoxybenzyl ester hydrochloride. Add phenol and react at 45 ° C for 1 hour to obtain 7-amino-3-vinyl_3-cefm-4 carboxylic acid.
- This compound can be converted to cefixime by the method described in JP-A-63-20435.
- the present invention has the following advantages over the prior art.
- a crystalline target substance can be obtained from amorphous powder or oily raw materials.
- the target product can be obtained simply by removing carbon dioxide, and the heat energy cost for drying is low.
- the target component Due to the large diffusivity of the supercritical fluid, the target component can be rapidly crystallized even from the tar-like viscous raw material reaction solution.
- Carbon dioxide is non-polluting, non-flammable, inexpensive and easy to recycle.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HK03100779.4A HK1049480B (en) | 1999-09-30 | 2000-09-28 | 3-cephem derivative crystal and method for preparing the same |
| EP00962912A EP1227100B1 (en) | 1999-09-30 | 2000-09-28 | 3-cephem derivative crystal and method for preparing the same |
| AT00962912T ATE267831T1 (de) | 1999-09-30 | 2000-09-28 | Kristalle von cephemderivaten und verfahren zu ihrer herstellung |
| US10/679,451 US6887992B2 (en) | 1999-09-30 | 2003-10-07 | 3-cephem derivative crystal |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11/278535 | 1999-09-30 | ||
| JP27853599 | 1999-09-30 | ||
| JP11/279080 | 1999-09-30 | ||
| JP27908099 | 1999-09-30 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10089194 A-371-Of-International | 2000-09-28 | ||
| US10/679,451 Division US6887992B2 (en) | 1999-09-30 | 2003-10-07 | 3-cephem derivative crystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001023393A1 true WO2001023393A1 (en) | 2001-04-05 |
Family
ID=26552911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2000/006693 Ceased WO2001023393A1 (en) | 1999-09-30 | 2000-09-28 | 3-cephem derivative crystal and method for preparing the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6887992B2 (ja) |
| EP (2) | EP1447406B1 (ja) |
| KR (1) | KR100494825B1 (ja) |
| AT (2) | ATE267831T1 (ja) |
| HK (1) | HK1049480B (ja) |
| WO (1) | WO2001023393A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104045655A (zh) * | 2014-06-23 | 2014-09-17 | 山东普洛得邦医药有限公司 | 一种抗菌素头孢母核的合成方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077849A1 (en) * | 2002-10-16 | 2004-04-22 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of cefadroxil |
| CN103622916B (zh) * | 2013-12-19 | 2015-04-08 | 石家庄市华新药业有限责任公司 | 一种头孢克肟干混悬制剂及其制备方法 |
| CN104693217B (zh) * | 2015-02-28 | 2017-01-11 | 浙江华方药业股份有限公司 | 一种头孢克肟的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0126351A1 (de) * | 1983-05-19 | 1984-11-28 | Fried. Krupp Gesellschaft mit beschränkter Haftung | Verfahren zur Isolierung und Reinigung von Antibiotika |
| EP0319019A2 (en) * | 1987-12-04 | 1989-06-07 | Takeda Chemical Industries, Ltd. | Crystals of cephem hydrochloride |
| WO1995007283A1 (en) * | 1993-09-09 | 1995-03-16 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH546794A (de) | 1970-06-18 | 1974-03-15 | Ciba Geigy Ag | Verfahren zur herstellung von cephalosporansaeurederivaten. |
| US3925372A (en) * | 1973-02-23 | 1975-12-09 | Lilly Co Eli | Alpha-aminoacyl-3-halo cephalosporins |
| US4694079A (en) * | 1985-07-29 | 1987-09-15 | Bristol-Myers Company | 3-propenyl cephalosporin solvates |
| JPH07121951B2 (ja) * | 1986-04-15 | 1995-12-25 | 武田薬品工業株式会社 | セファロスポリン系抗生物質の精製法 |
| US5707634A (en) * | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| EP0638573A1 (en) * | 1993-08-10 | 1995-02-15 | Lucky Ltd. | Crystalline hydrates of cephalosporin and process for preparation thereof |
| GB9423459D0 (en) * | 1994-11-21 | 1995-01-11 | Biochemie Gmbh | Silylation process |
| PL343099A1 (en) * | 1998-03-27 | 2001-07-30 | Dsm Nv | Novel process for the fermentative production of cephalosporin |
| US6221153B1 (en) * | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
| TWI250160B (en) * | 1999-07-06 | 2006-03-01 | Sankyo Co | Crystalline 1-methylcarbapenem compound |
-
2000
- 2000-09-28 EP EP04012048A patent/EP1447406B1/en not_active Expired - Lifetime
- 2000-09-28 HK HK03100779.4A patent/HK1049480B/en not_active IP Right Cessation
- 2000-09-28 KR KR10-2002-7003008A patent/KR100494825B1/ko not_active Expired - Fee Related
- 2000-09-28 WO PCT/JP2000/006693 patent/WO2001023393A1/ja not_active Ceased
- 2000-09-28 AT AT00962912T patent/ATE267831T1/de active
- 2000-09-28 AT AT04012048T patent/ATE335747T1/de active
- 2000-09-28 EP EP00962912A patent/EP1227100B1/en not_active Expired - Lifetime
-
2003
- 2003-10-07 US US10/679,451 patent/US6887992B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0126351A1 (de) * | 1983-05-19 | 1984-11-28 | Fried. Krupp Gesellschaft mit beschränkter Haftung | Verfahren zur Isolierung und Reinigung von Antibiotika |
| EP0319019A2 (en) * | 1987-12-04 | 1989-06-07 | Takeda Chemical Industries, Ltd. | Crystals of cephem hydrochloride |
| WO1995007283A1 (en) * | 1993-09-09 | 1995-03-16 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104045655A (zh) * | 2014-06-23 | 2014-09-17 | 山东普洛得邦医药有限公司 | 一种抗菌素头孢母核的合成方法 |
| CN104045655B (zh) * | 2014-06-23 | 2016-08-17 | 山东普洛得邦医药有限公司 | 一种抗菌素头孢母核的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1447406B1 (en) | 2006-08-09 |
| EP1227100A4 (en) | 2003-03-05 |
| KR20020032568A (ko) | 2002-05-03 |
| EP1227100A1 (en) | 2002-07-31 |
| HK1049480A1 (en) | 2003-05-16 |
| EP1447406A1 (en) | 2004-08-18 |
| US20040073023A1 (en) | 2004-04-15 |
| ATE335747T1 (de) | 2006-09-15 |
| KR100494825B1 (ko) | 2005-06-14 |
| US6887992B2 (en) | 2005-05-03 |
| ATE267831T1 (de) | 2004-06-15 |
| HK1049480B (en) | 2004-12-10 |
| EP1227100B1 (en) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3948628B2 (ja) | セフディニルの製造方法 | |
| JP2000514833A (ja) | 結晶性セフジニルアミン塩 | |
| KR920002869B1 (ko) | 7-아미노-3-치환된-메틸-3-세펨-4-카복실산 및 그의 저급 알킬실릴 유도체의 제조방법 | |
| JP3713282B2 (ja) | 3−(2−置換−ビニル)−セファロスポリンのz異性体の選択的製造方法 | |
| WO2001023393A1 (en) | 3-cephem derivative crystal and method for preparing the same | |
| KR0178280B1 (ko) | 세팔로스포린 항생제의 제조방법 | |
| JP3434839B2 (ja) | チアゾール中間体のシン異性体を用いたセファロスポリン抗生物質の製造法 | |
| JPH0553798B2 (ja) | ||
| JP4022070B2 (ja) | 新規チアゾール化合物およびその製造方法 | |
| JP4953501B2 (ja) | 3−セフェム誘導体結晶の製造方法 | |
| TW434244B (en) | Preparation of cephem-and isooxacephem derivatives | |
| JP3514495B2 (ja) | ハロゲン化アミノチアジアゾリル酢酸誘導体の製造法 | |
| JP5743474B2 (ja) | 4−アミノ−5−クロロ−2−エトキシ−n−〔[4−(4−フルオロベンジル)−2−モルホリニル]メチル〕ベンズアミドクエン酸塩2水和物の製造方法 | |
| HU193396B (en) | Process for producing a cepheme-carboxylic acid derivative /cephtazidim/ | |
| KR100643148B1 (ko) | 7-글루타릴이미드 세팔로스포란산 유도체와 이의 제조방법 | |
| CN105073759A (zh) | 头孢烯化合物 | |
| US4237280A (en) | Intermediate for cephalosporin type compound | |
| JPS6322585A (ja) | 6−トリフルオロメチル−1h−ベンゾトリアゾ−1−イル−ジフェニルホスフェイト及びセファロスポリン誘導体の製造方法 | |
| JP2525013B2 (ja) | 新規結晶性セファロスポリン誘導体 | |
| KR960011778B1 (ko) | 신규한 결정성 세팔로스포린 유도체의 제조방법 | |
| JP2001163888A (ja) | セファロスポリン結晶 | |
| JP2004002451A (ja) | 3−クロロメチル−3−セフェム誘導体結晶の製造方法 | |
| JP4659959B2 (ja) | 3−セフェム化合物及びその製造法 | |
| KR20250130961A (ko) | 신규한 유파다시티닙 결정형 i의 제조방법 및 신규한 유파다시티닙 결정형 i | |
| WO1999010352A1 (en) | Cephalosporin crystals and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1020027003008 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10089194 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000962912 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020027003008 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000962912 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2000962912 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1020027003008 Country of ref document: KR |